|32.06|| -0.08 / -0.25%|
Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others. The Global Generics segment is consist of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The PSAI segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with established pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates from hit generation to pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.
|Gunupati Venkateswara Prasad||Co-Chairman, Chief Executive Officer & MD|
|Saumen Chakraborty||President, CFO & Global Head-IT|
|Erez Israeli||Chief Operating Officer|
|Sandeep Poddar||Secretary & Compliance Officer|
|M. V. Ramana||EVP, Head-Emerging Markets & Global Generics|